Zealand Pharma A/S Reveals Breakthrough Weight Loss Outcomes in New Drug Trial
Friday, 21 June 2024, 12:12
Zealand Pharma A/S Delivers Breakthrough Weight Loss Outcomes
Key Points:
- Positive Results: Promising top-line findings from Phase 1b MAD trial.
- Competition Outshined: New drug poised to surpass Ozempic and WeGovy.
- Obesity Battle: Potential remedy brings hope in weight management landscape.
Danish biotech company Zealand Pharma A/S (OTC:ZLDPF) has announced encouraging topline results from a Phase 1b multiple ascending dose (MAD) trial...
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.